免疫組織化学（IHC）の世界市場：洞察、競合情勢、市場予測：2030年

世界の免疫組織化学（IHC）の市場規模は、2023年に25億6,000万米ドルとなりました。同市場は、2024年から2030年までの予測期間中に7.64％のCAGRで拡大し、2030年には39億8,000万米ドルに達すると予測されています。免疫組織化学（IHC）の需要増大は、主にがん、B型肝炎ウイルス、ヘルペスウイルスなどの慢性疾患や感染症の症例が増加していることに起因しています。さらに、様々な技術的に先進的なIHC製品の承認と発売の増加、IHC分野における自動化と機械学習のコンセプトの導入の増加、研究開発活動の増加などが、今後数年間の免疫組織化学（IHC）市場を牽引する要因の一部です。

免疫組織化学（IHC）市場は、世界中の人々の間で様々な感染症が急増しているため、現在勢いを増しています。これは、IHC技術が、多くの感染症の原因物質の検出と同定において、ウイルス、細菌、真菌、寄生虫抗原に対する特異的抗体を使用するためです。例えば、世界保健機関（WHO）2020年版によると、50歳未満の約37億人（67％）が単純ヘルペスウイルス1型（HSV-1）に感染しており、15～49歳の推定4億9,100万人（13％）が単純ヘルペスウイルス2型（HSV-2）に感染しています。

また、WHOの2022年の推計によると、2019年には約2億9,600万人が慢性B型肝炎に感染しています。

このように、世界の人口における様々な感染症の増加は、IHC検査の需要を高め、それによって世界のIHC市場の成長に寄与します。

当レポートでは、世界の免疫組織化学（IHC）市場について調査し、市場の概要とともに、製品タイプ別、用途別、エンドユーザー別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 免疫組織化学（IHC）市場レポートのイントロダクション

第2章 免疫組織化学（IHC）市場のエグゼクティブサマリー

第3章 規制分析

• 米国
• 欧州
• 日本
• 中国

第4章 免疫組織化学（IHC）市場の主な要因分析

• 免疫組織化学（IHC）市場の促進要因
• 免疫組織化学（IHC）市場の抑制要因と課題
• 免疫組織化学（IHC）市場の機会

第5章 免疫組織化学（IHC）市場におけるポーターのファイブフォース分析

第6章 免疫組織化学（IHC）市場に対するCOVID-19の影響分析

第7章 免疫組織化学（IHC）市場概要

• 製品タイプ別
• 用途別
• エンドユーザー別
• 地域別

第8章 免疫組織化学（IHC）世界企業シェア分析-主要3～5社

第9章 免疫組織化学（IHC）の企業と製品プロファイル

• F. Hoffmann-La Roche Ltd
• Agilent Technologies, Inc.
• Bio-Rad Laboratories, Inc.
• Thermo Fisher Scientific
• PerkinElmer Inc
• Danaher Corporation
• Merck KGaA
• Bio-Techne
• Genemed Biotechnologies, Inc
• Abcam plc
• Becton, Dickinson and Company
• Bio SB, Inc
• BioGenex
• Biocare Medical, LLC
• Diagnostic BioSystems Inc
• ROCKLAND IMMUNOCHEMICALS, INC
• Elabscience Biotechnology Inc
• Sakura Finetek USA, Inc
• CANDOR Bioscience GmbH
• NeoGenomics Laboratories

第10章 KOL の見解

第11章 プロジェクトのアプローチ

第12章 DelveInsightについて

第13章 免責事項とお問い合わせ

List of Tables

• Table 1: Competitive Analysis
• Table 2: COVID-19 Impact Analysis on Immunohistochemistry (IHC) Market
• Table 3: Immunohistochemistry (IHC) Market Analysis in Global (2021-2030)
• Table 4: Immunohistochemistry (IHC) Market Analysis in Global by Product Type (2021-2030)
• Table 5: Immunohistochemistry (IHC) Market Analysis in Global by Application (2021-2030)
• Table 6: Immunohistochemistry (IHC) Market Analysis in Global by End User (2021-2030)
• Table 7: Immunohistochemistry (IHC) Market Analysis in Global by Geography (2021-2030)
• Table 8: Immunohistochemistry (IHC) Market Analysis in North America (2021-2030)
• Table 9: Immunohistochemistry (IHC) Market Analysis in North America by Product Type (2021-2030)
• Table 10: Immunohistochemistry (IHC) Market Analysis in North America by Application (2021-2030)
• Table 11: Immunohistochemistry (IHC) Market Analysis in North America by End User (2021-2030)
• Table 12: Immunohistochemistry (IHC) Market Analysis in North America by Country (2021-2030)
• Table 13: Immunohistochemistry (IHC) Market Analysis in the US (2021-2030)
• Table 14: Immunohistochemistry (IHC) Market Analysis in Canada (2021-2030)
• Table 15: Immunohistochemistry (IHC) Market Analysis in Mexico (2021-2030)
• Table 16: Immunohistochemistry (IHC) Market Analysis in Europe (2021-2030)
• Table 17: Immunohistochemistry (IHC) Market Analysis in Europe by Product Type (2021-2030)
• Table 18: Immunohistochemistry (IHC) Market Analysis in Europe by Application (2021-2030)
• Table 19: Immunohistochemistry (IHC) Market Analysis in Europe by End User (2021-2030)
• Table 20: Immunohistochemistry (IHC) Market Analysis in Europe by Country (2021-2030)
• Table 21: Immunohistochemistry (IHC) Market Analysis in France (2021-2030)
• Table 22: Immunohistochemistry (IHC) Market Analysis in Germany (2021-2030)
• Table 23: Immunohistochemistry (IHC) Market Analysis in the UK (2021-2030)
• Table 24: Immunohistochemistry (IHC) Market Analysis in Italy (2021-2030)
• Table 25: Immunohistochemistry (IHC) Market Analysis in Spain (2021-2030)
• Table 26: Immunohistochemistry (IHC) Market Analysis in Russia (2021-2030)
• Table 27: Immunohistochemistry (IHC) Market Analysis in Rest of Europe (2021-2030)
• Table 28: Immunohistochemistry (IHC) Market Analysis in Asia-Pacific (2021-2030)
• Table 29: Immunohistochemistry (IHC) Market Analysis in Asia-Pacific by Product Type (2021-2030)
• Table 30: Immunohistochemistry (IHC) Market Analysis in Asia-Pacific by Application (2021-2030)
• Table 31: Immunohistochemistry (IHC) Market Analysis in Asia-Pacific by End User (2021-2030)
• Table 32: Immunohistochemistry (IHC) Market Analysis in Asia-Pacific by Country (2021-2030)
• Table 33: Immunohistochemistry (IHC) Market Analysis in China (2021-2030)
• Table 34: Immunohistochemistry (IHC) Market Analysis in Japan (2021-2030)
• Table 35: Immunohistochemistry (IHC) Market Analysis in India (2021-2030)
• Table 36: Immunohistochemistry (IHC) Market Analysis in Australia (2021-2030)
• Table 37: Immunohistochemistry (IHC) Market Analysis in South Korea (2021-2030)
• Table 38: Immunohistochemistry (IHC) Market Analysis in Rest of Asia-Pacific (2021-2030)
• Table 39: Immunohistochemistry (IHC) Market Analysis in Rest of World (2021-2030)
• Table 40: Immunohistochemistry (IHC) Market Analysis in Rest of World by Product Type (2021-2030)
• Table 41: Immunohistochemistry (IHC) Market Analysis in Rest of World by Application (2021-2030)
• Table 42: Immunohistochemistry (IHC) Market Analysis in Rest of World by End User (2021-2030)
• Table 43: Immunohistochemistry (IHC) Market Analysis in Rest of World by Country (2021-2030)
• Table 44: Immunohistochemistry (IHC) Market Analysis in the Middle East (2021-2030)
• Table 45: Immunohistochemistry (IHC) Market Analysis in Africa (2021-2030)
• Table 46: Immunohistochemistry (IHC) Market Analysis in South America (2021-2030)

List of Figures

• Figure 1: Competitive Analysis
• Figure 2: COVID-19 Impact Analysis on Immunohistochemistry (IHC) Market
• Figure 3: Immunohistochemistry (IHC) Market Analysis in Global (2021-2030)
• Figure 4: Immunohistochemistry (IHC) Market Analysis in Global by Product Type (2021-2030)
• Figure 5: Immunohistochemistry (IHC) Market Analysis in Global by Application (2021-2030)
• Figure 6: Immunohistochemistry (IHC) Market Analysis in Global by End User (2021-2030)
• Figure 7: Immunohistochemistry (IHC) Market Analysis in Global by Geography (2021-2030)
• Figure 8: Immunohistochemistry (IHC) Market Analysis in North America (2021-2030)
• Figure 9: Immunohistochemistry (IHC) Market Analysis in North America by Product Type (2021-2030)
• Figure 10: Immunohistochemistry (IHC) Market Analysis in North America by Application (2021-2030)
• Figure 11: Immunohistochemistry (IHC) Market Analysis in North America by End User (2021-2030)
• Figure 12: Immunohistochemistry (IHC) Market Analysis in North America by Country (2021-2030)
• Figure 13: Immunohistochemistry (IHC) Market Analysis in the US (2021-2030)
• Figure 14: Immunohistochemistry (IHC) Market Analysis in Canada (2021-2030)
• Figure 15: Immunohistochemistry (IHC) Market Analysis in Mexico (2021-2030)
• Figure 16: Immunohistochemistry (IHC) Market Analysis in Europe (2021-2030)
• Figure 17: Immunohistochemistry (IHC) Market Analysis in Europe by Product Type (2021-2030)
• Figure 18: Immunohistochemistry (IHC) Market Analysis in Europe by Application (2021-2030)
• Figure 19: Immunohistochemistry (IHC) Market Analysis in Europe by End User (2021-2030)
• Figure 20: Immunohistochemistry (IHC) Market Analysis in Europe by Country (2021-2030)
• Figure 21: Immunohistochemistry (IHC) Market Analysis in France (2021-2030)
• Figure 22: Immunohistochemistry (IHC) Market Analysis in Germany (2021-2030)
• Figure 23: Immunohistochemistry (IHC) Market Analysis in the UK (2021-2030)
• Figure 24: Immunohistochemistry (IHC) Market Analysis in Italy (2021-2030)
• Figure 25: Immunohistochemistry (IHC) Market Analysis in Spain (2021-2030)
• Figure 26: Immunohistochemistry (IHC) Market Analysis in Russia (2021-2030)
• Figure 27: Immunohistochemistry (IHC) Market Analysis in Rest of Europe (2021-2030)
• Figure 28: Immunohistochemistry (IHC) Market Analysis in Asia-Pacific (2021-2030)
• Figure 29: Immunohistochemistry (IHC) Market Analysis in Asia-Pacific by Product Type (2021-2030)
• Figure 30: Immunohistochemistry (IHC) Market Analysis in Asia-Pacific by Application (2021-2030)
• Figure 31: Immunohistochemistry (IHC) Market Analysis in Asia-Pacific by End User (2021-2030)
• Figure 32: Immunohistochemistry (IHC) Market Analysis in Asia-Pacific by Country (2021-2030)
• Figure 33: Immunohistochemistry (IHC) Market Analysis in China (2021-2030)
• Figure 34: Immunohistochemistry (IHC) Market Analysis in Japan (2021-2030)
• Figure 35: Immunohistochemistry (IHC) Market Analysis in India (2021-2030)
• Figure 36: Immunohistochemistry (IHC) Market Analysis in Australia (2021-2030)
• Figure 37: Immunohistochemistry (IHC) Market Analysis in South Korea (2021-2030)
• Figure 38: Immunohistochemistry (IHC) Market Analysis in Rest of Asia-Pacific (2021-2030)
• Figure 39: Immunohistochemistry (IHC) Market Analysis in Rest of World (2021-2030)
• Figure 40: Immunohistochemistry (IHC) Market Analysis in Rest of World by Product Type (2021-2030)
• Figure 41: Immunohistochemistry (IHC) Market Analysis in Rest of World by Application (2021-2030)
• Figure 42: Immunohistochemistry (IHC) Market Analysis in Rest of World by End User (2021-2030)
• Figure 43: Immunohistochemistry (IHC) Market Analysis in Rest of World by Country (2021-2030)
• Figure 44: Immunohistochemistry (IHC) Market Analysis in the Middle East (2021-2030)
• Figure 45: Immunohistochemistry (IHC) Market Analysis in Africa (2021-2030)
• Figure 46: Immunohistochemistry (IHC) Market Analysis in South America (2021-2030)
• Figure 47: Market Drivers
• Figure 48: Market Barriers
• Figure 49: Market Opportunities
• Figure 50: PORTER's Five Force Analysis

Immunohistochemistry (IHC) Market By Product Type (Instruments, Reagents & Kits, Services), By Application (Diagnostic, Research, Others), By End-User (Hospitals & Diagnostic Laboratories, Academic & Research Institutes, Others), by geography, is expected to grow at a constant CAGR forecast till 2030 owing to the rising usage of immunohistochemistry (IHC) technology in clinical diagnosis and advancement in IHC products

The global immunohistochemistry (IHC) market was valued at USD 2.56 billion in 2023, growing at a CAGR of 7.64% during the forecast period from 2024 to 2030, to reach USD 3.98 billion by 2030. The growing demand for immunohistochemistry (IHC) is predominantly attributed to the rising cases of chronic and infectious diseases such as cancer, hepatitis B virus, herpes virus, among others. Moreover, the rise in approval and launch of various technologically advanced IHC products, and growing implementation of automation and machine learning concepts in the field of IHC, and increase in research and development activities, among others are some of the factors responsible for driving the Immunohistochemistry (IHC) market in the upcoming years.

Immunohistochemistry (IHC) Market Dynamics:

The market for immunohistochemistry (IHC) is gaining momentum at present due to the surge in various infectious diseases among the population across the globe. This is because the IHC technique uses specific antibodies to viral, bacterial, fungal, and parasitic antigens in the detection and identification of the causative agents in many infectious diseases. For instance, approximately 3.7 billion people under age 50 (67%) have herpes simplex virus type 1 (HSV-1) infection, and an estimated 491 million people aged 15-49 (13%) have herpes simplex virus type 2 (HSV-2) infection globally as per the World Health Organization (WHO) 2020.

In addition, as per the WHO 2022 estimates, approximately 296 million people were living with chronic hepatitis B infection in the year 2019.

Thus, rising various infectious disorders in the worldwide population would raise the demand for IHC testing thereby contributing to the global IHC market growth.

In addition, the increasing burden of cancer cases worldwide is also anticipated to contribute to the Immunohistochemistry (IHC) market. This is because IHC is widely used for the diagnosis of cancers and specific tumor antigens that are expressed de novo or up-regulated in certain cancers. According to the data published by the GLOBOCAN directory in the year 2020, approximately 19,292,789 new cases of cancer were detected, globally in the same year.

However, certain factors such as the risk of false-positive results and the high cost of the instruments are likely to impede the Immunohistochemistry (IHC) market growth.

Also, the unprecedented COVID-19 outbreak had slowed down the overall immunohistochemistry market. This is due to the temporary halt in manufacturing facilities, reduction in the screening process of various diseases such as cancer, and others due to the impose of lockdown restrictions across the globe. However, the pandemic has also provided opportunities for IHC product manufacturers as they have undertaken initiatives to overcome the challenges posed by this pandemic and shifted their business focus by introducing IHC products for COVID-19 research. For instance, Bio SB, a US-based company has developed and manufactured the CoV-2 recombinant proteins and peptides needed to generate antibodies to identify the virus, receptors, and IL's by Immunohistochemistry and Immunofluorescence on FFPE biopsies. Moreover, due to the launch of various vaccines and mass vaccination drive the market for IHC is likely to regain normalcy owing to the relaxation in restrictions.

Immunohistochemistry (IHC) Market Segment Analysis:

Immunohistochemistry (IHC) Market By Product Type (Instruments, Reagents & Kits, Services), By Application (Diagnostic, Research, Others), By End-User (Hospitals & Diagnostic Laboratories, Academic & Research Institutes, Others), and By Geography (North America, Europe, Asia-Pacific, and Rest of the World).

In the Immunohistochemistry (IHC) product type segment, the reagents & kits segment is anticipated to hold a significant market share during the forthcoming years. This is because of the wide availability of regents and kits products in the market for the specific application. In addition, the kits minimize the chances of errors by eliminating the selection procedure for use of an appropriate combination of antibodies and stains against a tissue sample.

Moreover, the IHC kits are widely used in research laboratories due to their compact nature and availability of products in small quantities for carrying research and rising research and development activities across the globe would contribute to the segmental market in the upcoming years.

In addition, approval of reagents and kits in recent years is also expected to augment the segmental market for immunohistochemistry (IHC) market. For instance, on March 06, 2020, Leica Biosystems (Danaher Corporation) received FDA clearance for BOND Ready-to-Use Primary Antibody Progesterone Receptor and Novocastra Liquid Mouse Monoclonal Antibody Progesterone Receptor Clone (Immunohistochemistry reagents and kits).

Thus, all the above-mentioned factors will contribute to the segment growth in the forthcoming years.

North America is expected to dominate the overall Immunohistochemistry (IHC) Market:

Among all the regions, North America is expected to occupy a major share in the overall Immunohistochemistry (IHC) market during the forecasted period. This domination is owing to the growing cases of infectious disease in the region. Furthermore, the surge in the new cancer cases, the presence of key market players, and their strategic business activities, among others are expected to fuel the overall Immunohistochemistry (IHC) market in the region.

For instance, according to the data published by the GLOBOCAN directory in the year 2020, approximately, 2,281,658 new cases of cancer were reported in the US in the same year.

Moreover, the adoption of technologically advanced IHC products and instruments in the region would also raise the market for IHC in the region.

Furthermore, as per the Government of Canada 2018 report, there were a total of 4,783 cases and 12,477 cases of hepatitis B and hepatitis C respectively in Canada.

Additionally, the approval of various IHC products as companion diagnostic for cancer in the region would also raise the market for immunohistochemistry in the upcoming years.

For instance, in November 2020, FDA Approves PD-L1 IHC 22C3 pharmDx as Companion Diagnostic for Pembrolizumab. The FDA approved the use of PD-L1 IHC 22C3 pharmDx as an aid in identifying patients with triple-negative breast cancer who may be appropriate for treatment with pembrolizumab (Keytruda).

Thus, all the above-mentioned factors are likely to grow the market for IHC in the region during the forecasted period.

Immunohistochemistry (IHC) Market Key Players:

Some of the key market players operating in the Immunohistochemistry (IHC) market include Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific, PerkinElmer Inc., Danaher Corporation, Merck KGaA, Bio-Techne., Genemed Biotechnologies, Inc., Abcam plc, Becton, Dickinson and Company, Bio SB, Inc., BioGenex., Biocare Medical, LLC., Diagnostic BioSystems Inc., ROCKLAND IMMUNOCHEMICALS, INC., Elabscience Biotechnology Inc., Sakura Finetek USA, Inc., CANDOR Bioscience GmbH, NeoGenomics Laboratories., among others.

Recent Developmental Activities in the Immunohistochemistry (IHC) Market:

On July 20, 2022, Agilent Technologies Inc.'s PD-L1 IHC 22C3 pharmDx assay was labeled for expanded use in patients with non-small cell lung cancer (NSCLC) in the European Union.

On April 23, 2022, Roche received FDA approval for the VENTANA MMR RxDx Panel, the first immunohistochemistry predictive test in endometrial cancer for treatment with the anti-PD1 immunotherapy JEMPERLI (dostarlimab-gxly).

On March 18, 2022, Roche launched the DISCOVERY Green HRP kit, the newest addition to the comprehensive collection of modular-based detection kits to identify and profile biomarkers and cell populations in tissue-based research. The DISCOVERY Green HRP (horseradish peroxidase) kit can be used in combination with other detection kits, expanding the multiplexing capability of both immunohistochemistry (IHC) and in situ hybridization (ISH) by providing a distinct color that contrasts with other chromogens.

Key Takeaways from the Immunohistochemistry (IHC) Market Report Study

• Market size analysis for current market size (2023), and market forecast for 5 years (2024-2030)
• The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the Immunohistochemistry (IHC) market.
• Top key product/services/technology developments, merger, acquisition, partnership, joint venture happened for last 3 years
• Key companies dominating the Global Immunohistochemistry (IHC) Market.
• Various opportunities available for the other competitor in the Immunohistochemistry (IHC) Market space.
• What are the top-performing segments in 2023? How these segments will perform in 2030.
• Which are the top-performing regions and countries in the current market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for Immunohistochemistry (IHC) market growth in the coming future?

Target Audience who can be benefited from the Immunohistochemistry (IHC) Market Report Study

• Immunohistochemistry (IHC) providers
• Research organizations and consulting companies
• Immunohistochemistry (IHC)-related organization, association, forum, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and Traders in Immunohistochemistry (IHC)
• Various End-users who want to know more about the Immunohistochemistry (IHC) Market and the latest technological developments in the Immunohistochemistry (IHC) market.

Frequently Asked Questions for the Immunohistochemistry (IHC) Market:

1. What is Immunohistochemistry (IHC)?

Immunohistochemistry (IHC) is a technique that uses antibodies to check for certain antigens (markers) in a sample of tissue. The antibodies are usually linked to an enzyme or a fluorescent dye.

2. What is the market for Global Immunohistochemistry (IHC)?

The global Immunohistochemistry (IHC) Market was valued at USD 2.56 billion in 2023, growing at a CAGR of 7.64% during the forecast period from 2024 to 2030 to reach USD 3.98 billion by 2030.

3. What are the drivers for Global Immunohistochemistry (IHC)?

The major factors driving the demand for Immunohistochemistry (IHC) are the rising cases of chronic and infectious diseases such as cancer, hepatitis B virus, herpes virus, among others. Moreover, the rise in approval and launch of various technologically advanced IHC products, and growing implementation of automation and machine learning concepts in the field of IHC, and increase in research and development activities, among others are some of the factors responsible for driving the Immunohistochemistry (IHC) market in the upcoming years.

4. What are the key players operating in Global Immunohistochemistry (IHC)?

Some of the key market players operating in the Immunohistochemistry (IHC) market include Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific, PerkinElmer Inc., Danaher Corporation, Merck KGaA, Bio-Techne., Genemed Biotechnologies, Inc., Abcam plc, Becton, Dickinson and Company, Bio SB, Inc., BioGenex., Biocare Medical, LLC., Diagnostic BioSystems Inc., ROCKLAND IMMUNOCHEMICALS, INC., Elabscience Biotechnology Inc., Sakura Finetek USA, Inc., CANDOR Bioscience GmbH, NeoGenomics Laboratories., among others.

5. Which region has the highest share in the Immunohistochemistry (IHC) market?

Among all the regions, North America is expected to occupy a major share in the overall Immunohistochemistry (IHC) market during the forecasted period, 2024-2030. This domination is owing to the growing cases of infectious disease in the region. Furthermore, the surge in the new cancer cases, the presence of key market players, and their strategic business activities, among others are expected to fuel the overall Immunohistochemistry (IHC) market in the region.

Table of Contents

1.Immunohistochemistry (IHC) Market Report Introduction

2.Immunohistochemistry (IHC) Market Executive summary

• 2.1. Scope of the Study
• 2.2. Market at Glance
• 2.3. Competitive Assessment
• 2.4. Financial Benchmarking

3. Regulatory Analysis

• 3.1. The United States
• 3.2. Europe
• 3.3. Japan
• 3.4. China

4. Immunohistochemistry (IHC) Market Key factors analysis

• 4.1. Immunohistochemistry (IHC) Market Drivers
  • 4.1.1. The rising burden of cancer worldwide
  • 4.1.2. Growing incidence of infectious diseases such as hepatitis B, and others across the globe
  • 4.1.3. Rapid approval and launch of Immunohistochemistry (IHC) products
  • 4.1.4. Technological advancement in the manufacturing of Immunohistochemistry (IHC) products
• 4.2. Immunohistochemistry (IHC) Market Restraints and Challenges
  • 4.2.1. High cost associated with Immunohistochemistry (IHC) instruments and services
  • 4.2.2. Risk of False-Positive Results
• 4.3. Immunohistochemistry (IHC) Market Opportunities
  • 4.3.1. Low and middle-income nations have tremendous opportunities for the Immunohistochemistry (IHC) market
  • 4.3.2. Strategic business activities by the global as well as regional manufacturers will provide opportunities in the Immunohistochemistry (IHC) market

5. Immunohistochemistry (IHC) Porter's Five Forces Analysis

• 5.1. Bargaining Power of Suppliers
• 5.2. Bargaining Power of Consumers
• 5.3. Threat of New Entrants
• 5.4. Threat of Substitutes
• 5.5. Competitive Rivalry

6. COVID-19 Impact Analysis on Immunohistochemistry (IHC) Market

7. Immunohistochemistry (IHC) Market layout

• 7.1. By Product Type
  • 7.1.1. Instruments
  • 7.1.2. Reagents & Kits
  • 7.1.3. Services
• 7.2. By Application
  • 7.2.1. Diagnostic
  • 7.2.2. Research
  • 7.2.3. Forensic
• 7.3. By End-user
  • 7.3.1. Hospitals & Diagnostic Laboratories
  • 7.3.2. Academic & research Institutes
  • 7.3.3. Others
• 7.4. By Geography
  • 7.5.1 North America
    • 7.4.1.1. North America Immunohistochemistry (IHC) Market, by Product Type
    • 7.4.1.2. North America Immunohistochemistry (IHC) Market, by Application
    • 7.4.1.3. North America Immunohistochemistry (IHC) Market, by End User
    • 7.4.1.4. North America Immunohistochemistry (IHC) Market, by Country
    • 7.4.1.4.1. United States
    • 7.4.1.4.2. Canada
    • 7.4.1.4.3. Mexico
  • 7.4.2. Europe
    • 7.4.2.1. Europe Immunohistochemistry (IHC) Market, by Product Type
    • 7.4.2.2. Europe Immunohistochemistry (IHC) Market, by Application
    • 7.4.2.3. Europe Immunohistochemistry (IHC) Market, by End User
    • 7.4.2.4. Europe Immunohistochemistry (IHC) Market, by Country
    • 7.4.2.4.1. France
    • 7.4.2.4.2. Germany
    • 7.4.2.4.3. United Kingdom
    • 7.4.2.4.4. Italy
    • 7.4.2.4.5. Spain
    • 7.4.2.4.6. Russia
    • 7.4.2.4.7. Rest of Europe
  • 7.4.3. Asia-Pacific
    • 7.4.3.1. Asia-Pacific Immunohistochemistry (IHC) Market, by Product Type
    • 7.4.3.2. Asia-Pacific Immunohistochemistry (IHC) Market, by Application
    • 7.4.3.3. Asia-Pacific Immunohistochemistry (IHC) Market, by End User
    • 7.4.3.4. Asia-Pacific Immunohistochemistry (IHC) Market, by Country
    • 7.4.3.4.1. China
    • 7.4.3.4.2. Japan
    • 7.4.3.4.3. India
    • 7.4.3.4.4. Australia
    • 7.4.3.4.5. South Korea
    • 7.4.3.4.6. Rest of Asia Pacific
  • 7.4.4. Rest of the World (RoW)
    • 7.4.4.1. RoW Immunohistochemistry (IHC) Market, by Product Type
    • 7.4.4.2. RoW Immunohistochemistry (IHC) Market, by Application
    • 7.4.4.3. RoW Immunohistochemistry (IHC) Market, by End User
    • 7.4.4.4. RoW Immunohistochemistry (IHC) Market, by Region
    • 7.4.4.4.1. Middle East
    • 7.4.4.4.2. Africa
    • 7.4.4.4.3. South America

8. Immunohistochemistry (IHC) Global Company Share Analysis - Key 3-5 Companies

9. Immunohistochemistry (IHC) Company and Product Profiles

• 9.1. F. Hoffmann-La Roche Ltd
  • 9.1.1. Company Overview
  • 9.1.2. Company Snapshot
  • 9.1.3. Financial Overview
  • 9.1.4. Product Listing
  • 9.1.5. Entropy
• 9.2. Agilent Technologies, Inc.
  • 9.2.1. Company Overview
  • 9.2.2. Company Snapshot
  • 9.2.3. Financial Overview
  • 9.2.4. Product Listing
  • 9.2.5. Entropy
• 9.3. Bio-Rad Laboratories, Inc.
  • 9.3.1. Company Overview
  • 9.3.2. Company Snapshot
  • 9.3.3. Financial Overview
  • 9.3.4. Product Listing
  • 9.3.5. Entropy
• 9.4. Thermo Fisher Scientific
  • 9.4.1. Company Overview
  • 9.4.2. Company Snapshot
  • 9.4.3. Financial Overview
  • 9.4.4. Product Listing
  • 9.4.5. Entropy
• 9.5. PerkinElmer Inc
  • 9.5.1. Company Overview
  • 9.5.2. Company Snapshot
  • 9.5.3. Financial Overview
  • 9.5.4. Product Listing
  • 9.5.5. Entropy
• 9.6. Danaher Corporation
  • 9.6.1. Company Overview
  • 9.6.2. Company Snapshot
  • 9.6.3. Financial Overview
  • 9.6.4. Product Listing
  • 9.6.5. Entropy
• 9.7. Merck KGaA
  • 9.7.1. Company Overview
  • 9.7.2. Company Snapshot
  • 9.7.3. Financial Overview
  • 9.7.4. Product Listing
  • 9.7.5. Entropy
• 9.8. Bio-Techne
  • 9.8.1. Company Overview
  • 9.8.2. Company Snapshot
  • 9.8.3. Financial Overview
  • 9.8.4. Product Listing
  • 9.8.5. Entropy
• 9.9. Genemed Biotechnologies, Inc
  • 9.9.1. Company Overview
  • 9.9.2. Company Snapshot
  • 9.9.3. Financial Overview
  • 9.9.4. Product Listing
  • 9.9.5. Entropy
• 9.10. Abcam plc
  • 9.10.1. Company Overview
  • 9.10.2. Company Snapshot
  • 9.10.3. Financial Overview
  • 9.10.4. Product Listing
  • 9.10.5. Entropy
• 9.11. Becton, Dickinson and Company
  • 9.11.1. Company Overview
  • 9.11.2. Company Snapshot
  • 9.11.3. Financial Overview
  • 9.11.4. Product Listing
  • 9.11.5. Entropy
• 9.12. Bio SB, Inc
  • 9.12.1. Company Overview
  • 9.12.2. Company Snapshot
  • 9.12.3. Financial Overview
  • 9.12.4. Product Listing
  • 9.12.5. Entropy
• 9.13. BioGenex
  • 9.13.1. Company Overview
  • 9.13.2. Company Snapshot
  • 9.13.3. Financial Overview
  • 9.13.4. Product Listing
  • 9.13.5. Entropy
• 9.14. Biocare Medical, LLC
  • 9.14.1. Company Overview
  • 9.14.2. Company Snapshot
  • 9.14.3. Financial Overview
  • 9.14.4. Product Listing
  • 9.14.5. Entropy
• 9.15. Diagnostic BioSystems Inc
  • 9.15.1. Company Overview
  • 9.15.2. Company Snapshot
  • 9.15.3. Financial Overview
  • 9.15.4. Product Listing
  • 9.15.5. Entropy
• 9.16. ROCKLAND IMMUNOCHEMICALS, INC
  • 9.16.1. Company Overview
  • 9.16.2. Company Snapshot
  • 9.16.3. Financial Overview
  • 9.16.4. Product Listing
  • 9.16.5. Entropy
• 9.17. Elabscience Biotechnology Inc
  • 9.17.1. Company Overview
  • 9.17.2. Company Snapshot
  • 9.17.3. Financial Overview
  • 9.17.4. Product Listing
  • 9.17.5. Entropy
• 9.18. Sakura Finetek USA, Inc
  • 9.18.1. Company Overview
  • 9.18.2. Company Snapshot
  • 9.18.3. Financial Overview
  • 9.18.4. Product Listing
  • 9.18.5. Entropy
• 9.19. CANDOR Bioscience GmbH
  • 9.19.1. Company Overview
  • 9.19.2. Company Snapshot
  • 9.19.3. Financial Overview
  • 9.19.4. Product Listing
  • 9.19.5. Entropy
• 9.20. NeoGenomics Laboratories
  • 9.20.1. Company Overview
  • 9.20.2. Company Snapshot
  • 9.20.3. Financial Overview
  • 9.20.4. Product Listing
  • 9.20.5. Entropy

10. KOL Views

11. Project Approach

12. About DelveInsight

13. Disclaimer & Contact Us